Johnson & Johnson Proposes $5.5 Billion Settlement to Resolve Talc Litigation

Johnson & Johnson said on Monday it has put forward a $5.5 billion settlement proposal aimed at ending tens of thousands of lawsuits tied to its talc-based baby powder products. The claims allege the products caused ovarian cancer and were contaminated with asbestos, allegations that have been part of a legal dispute stretching back to 2009.

The company said the offer is intended to bring the long-running litigation to a close through a structured payout. It framed the approach as a way to reduce the ongoing cost of fighting the cases and to remove uncertainty that has lingered over its financial position.

Settlement aims to conclude dispute dating to 2009

According to the company According to the company, the proposal is designed to consolidate the talc-related claims into a single resolution process. Johnson & Johnson has repeatedly said the allegations are without merit and has maintained that its products are safe.

The lawsuits, as described by the company’s announcement, include allegations that talc products were contaminated with asbestos and that this exposure contributed to ovarian cancer. The settlement offer, if completed, would address the volume of cases that have accumulated over years of litigation.

Strategic shift after product change in 2022 Johnson & Johnson noted that it moved its global baby powder portfolio to cornstarch-based alternatives in 2022. That transition marked a significant change in the company’s consumer product lineup, even as legal proceedings connected to the earlier talc products continued.

The company said the settlement would function as The company said the settlement would function as a strategic exit from a prolonged period of legal exposure. It also described the arrangement as a way to limit further litigation-related spending and to reduce uncertainty tied to these claims.

Company cites focus on pharmaceuticals and devices

Johnson & Johnson’s announcement comes despite recent court rulings that questioned the causal link between talc and ovarian cancer. The company said it nevertheless chose to pursue a settlement path as it seeks to redirect attention and resources toward its core pharmaceutical and medical device operations.

The company said the financial impact of the proposal is expected to be finalized as it works to consolidate the claims. It added that the resolution process is expected to play out over the coming months, as legal requirements needed to implement the settlement are met.

For now, the outcome depends on the steps required to satisfy those legal conditions, and the company indicated the process will continue over the months ahead while the settlement mechanism is evaluated and advanced.

Implications

Country Impact: The announcement signals a major attempt by a U.S.-based multinational to close a legal dispute that has lasted for years. The process may remain uncertain in the near term because the settlement must meet legal requirements over the coming months.

Industry Impact: For pharmaceuticals and medical devices within Johnson & Johnson, the company said the settlement is intended to free resources and management attention. The move also underscores how legacy consumer-product litigation can remain a significant issue even after product portfolios change.

Market Impact: Johnson & Johnson said the structured payout is meant to reduce litigation costs and remove uncertainty from its balance sheet. The final financial impact will depend on how the consolidation of claims proceeds and whether the settlement conditions are satisfied.